<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>LORTAB- hydrocodone bitartrate and acetaminophenÂ tabletÂ </strong><br>Rx Pak Division of McKesson Corporation<br></p></div>
<h1>LORTAB<span class="Sup">Â®</span> 5/500 <br>Hydrocodone Bitartrate and Acetaminophen Tablets, USP <br>5 mg/500 mg</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a357638c-add6-4250-a31b-b21e9b1af678"></a><a name="section-1"></a><p></p>
<p class="First"><span class="Bold">CIII<br>Rx only</span></p>
</div>
<div class="Warning">
<a name="id_64ef7456-f3e1-4f25-8beb-995c84ccfc65"></a><a name="section-2"></a><p></p>
<h1></h1>
<p class="First">Hepatotoxicity</p>
<p><span class="Bold">Acetaminophen has been associated with cases of <span class="product-label-link" type="condition" conceptid="4026032" conceptname="Acute hepatic failure">acute liver failure</span>, at times resulting in liver transplant and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Most of the cases of <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> are associated with the use of acetaminophen at doses that exceed 4000 milligrams per day, and often involve more than one acetaminophen-containing product (see <a href="#i4i_warnings_id_9d226fd8-f719-45f2-9108-71ba7e300bfe">WARNINGS</a>).</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_618cf01e-7726-4522-bf35-8ea19ab09f29"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Hydrocodone bitartrate and acetaminophen is supplied in tablet form for oral administration.</p>
<p><span class="Bold">WARNING: May be habit-forming</span> (see <a href="#i4i_precautions_id_d2e4450b-93fe-4c31-afea-c0a262f2561d">PRECAUTIONS, Information For Patients/Caregivers</a>, and <a href="#i4i_abuse_dependence_id_fca7add3-546a-4f72-91e1-17ddc4f99fb9">DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></a>).</p>
<p>Hydrocodone bitartrate is an opioid analgesic and antitussive and occurs as fine, white crystals or as a crystalline powder. It is affected by light. The chemical name is 4,5Î±-epoxy-3-methoxy-17-methylmorphinan-6-one tartrate (1:1) hydrate (2:5). It has the following structural formula:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6e48680d-b4ea-4eca-86ab-d9eb3434855b&amp;name=6e48680d-b4ea-4eca-86ab-d9eb3434855b-01.jpg"></div>
<p>Acetaminophen, 4â€²-hydroxyacetanilide, a slightly bitter, white, odorless, crystalline powder, is a non-opiate, non-salicylate analgesic and antipyretic. It has the following structural formula:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6e48680d-b4ea-4eca-86ab-d9eb3434855b&amp;name=6e48680d-b4ea-4eca-86ab-d9eb3434855b-02.jpg"></div>
<p>Each LORTAB 5/500 tablet contains:</p>
<p>Hydrocodone Bitartrate......................................................5 mg<br>Acetaminophen...............................................................500 mg</p>
<p>In addition, each tablet contains the following inactive ingredients: cornstarch, FD&amp;C Blue #1 Lake, gelatin, magnesium stearate, microcrystalline cellulose, povidone, pregelatinized starch, sodium starch glycolate, and sugar spheres. Meets USP dissolution test 1.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_49992e7c-5901-4061-8600-cdbfb2874690"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Hydrocodone is a semisynthetic narcotic analgesic and antitussive with multiple actions qualitatively similar to those of codeine. Most of these involve the central nervous system and smooth muscle. The precise mechanism of action of hydrocodone and other opiates is not known, although it is believed to relate to the existence of opiate receptors in the central nervous system. In addition to <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span>, narcotics may produce <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, changes in mood and mental clouding.</p>
<p>The analgesic action of acetaminophen involves peripheral influences, but the specific mechanism is as yet undetermined. Antipyretic activity is mediated through hypothalamic heat regulating centers. Acetaminophen inhibits prostaglandin synthetase. Therapeutic doses of acetaminophen have negligible effects on the cardiovascular or respiratory systems; however, toxic doses may cause <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">circulatory failure</span> and rapid, <span class="product-label-link" type="condition" conceptid="4302536" conceptname="Shallow breathing">shallow breathing</span>.</p>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_a0f4ef1a-6dae-413d-ab16-e2719926bf5c"></a><a name="section-3.1"></a><p></p>
<p class="First"><span class="Bold">Pharmacokinetics </span></p>
<p>The behavior of the individual components is described below.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_60b310af-0718-4e4c-b803-844e26c673a8"></a><a name="section-3.2"></a><p></p>
<p class="First"> Hydrocodone</p>
<p>Following a 10 mg oral dose of hydrocodone administered to five adult male subjects, the mean peak concentration was 23.6 Â± 5.2 ng/mL. Maximum serum levels were achieved at 1.3 Â± 0.3 hours and the half-life was determined to be 3.8 Â± 0.3 hours. Hydrocodone exhibits a complex pattern of metabolism including O-demethylation, N-demethylation and 6-keto reduction to the corresponding 6-Î±- and 6-Î²-hydroxymetabolites.</p>
<p>See <span class="Bold"><a href="#i4i_overdosage_id_8e8ea00f-5049-4f0b-ac81-04b2d42f5fba">OVERDOSAGE</a></span> for toxicity information.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9d7b95ba-e1bf-4148-b140-d98118969daf"></a><a name="section-3.3"></a><p></p>
<p class="First"> Acetaminophen</p>
<p>Acetaminophen is rapidly absorbed from the gastrointestinal tract and is distributed throughout most body tissues. The plasma half-life is 1.25 to 3 hours, but may be increased by <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver damage</span> and following overdosage. Elimination of acetaminophen is principally by liver metabolism (conjugation) and subsequent renal excretion of metabolites. Approximately 85% of an oral dose appears in the urine within 24 hours of administration, most as the glucuronide conjugate, with small amounts of other conjugates and unchanged drug.</p>
<p>See <span class="Bold"><a href="#i4i_overdosage_id_8e8ea00f-5049-4f0b-ac81-04b2d42f5fba">OVERDOSAGE</a></span> for toxicity information. </p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_8cf90e11-995f-4e40-9ed2-7e7b6ca5982d"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">LORTAB 5/500 tablets (hydrocodone bitartrate and acetaminophen tablets, USP, 5 mg/500 mg) are indicated for the relief of moderate to moderately severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_0db2eb68-36b2-477a-84a4-49018194d32d"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">This product should not be administered to patients who have previously exhibited <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to hydrocodone or acetaminophen.</p>
<p>Patients known to be hypersensitive to other opioids may exhibit cross sensitivity to hydrocodone.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_9d226fd8-f719-45f2-9108-71ba7e300bfe"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_72172e91-0ba9-4175-8d14-eefd610771a0"></a><a name="section-6.1"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span> </span></p>
<p>At high doses or in sensitive patients, hydrocodone may produce dose-related <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> by acting directly on the brain stem respiratory center. Hydrocodone also affects the center that controls respiratory rhythm, and may produce irregular and periodic breathing.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2f7e7077-8c80-444b-a8cc-d3cde9382976"></a><a name="section-6.2"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">Head Injury</span> And <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">Increased Intracranial Pressure</span></span></p>
<p>The respiratory depressant effects of narcotics and their capacity to elevate cerebrospinal fluid pressure may be markedly exaggerated in the presence of <span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">head injury</span>, other intracranial lesions or a preexisting increase in intracranial pressure. Furthermore, narcotics produce adverse reactions which may obscure the clinical course of patients with head injuries.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d1e8c543-85c7-4fa6-8e3b-120992c2aa75"></a><a name="section-6.3"></a><p></p>
<p class="First"><span class="Bold">Acute Abdominal Conditions </span></p>
<p>The administration of narcotics may obscure the diagnosis or clinical course of patients with acute abdominal conditions.</p>
<p><span class="Bold">Misuse, Abuse, And Diversion Of Opioids</span></p>
<p>LORTAB 5/500 tablets contains hydrocodone, an opioid agonist, and is a Schedule III controlled substance. Opioid agonists have the potential for being abused and are sought by abusers and people with addiction disorders, and are subject to diversion.</p>
<p>LORTAB 5/500 tablets can be abused in a manner similar to other opioid agonists, legal or illicit. This should be considered when prescribing or dispensing LORTAB 5/500 tablets in situations where the physician or pharmacist is concerned about an increased risk of misuse, abuse or diversion (<span class="Italics">see </span><span class="Bold"><a href="#i4i_abuse_dependence_id_fca7add3-546a-4f72-91e1-17ddc4f99fb9">DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></a></span>).</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d89ac01d-95e8-4a86-8ca7-0e82c1f919e5"></a><a name="section-6.3.1"></a><p></p>
<p class="First"><span class="Bold">Hepatotoxicity</span></p>
<p>Acetaminophen has been associated with cases of <span class="product-label-link" type="condition" conceptid="4026032" conceptname="Acute hepatic failure">acute liver failure</span>, at times resulting in liver transplant and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Most of the cases of <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> are associated with the use of acetaminophen at doses that exceed 4000 milligrams per day, and often involve more than one acetaminophen-containing product. The excessive intake of acetaminophen may be intentional to cause self-harm or unintentional as patients attempt to obtain more <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> relief or unknowingly take other acetaminophen-containing products.</p>
<p>The risk of <span class="product-label-link" type="condition" conceptid="4026032" conceptname="Acute hepatic failure">acute liver failure</span> is higher in individuals with underlying liver disease and in individuals who ingest alcohol while taking acetaminophen.</p>
<p>Instruct patients to look for acetaminophen or APAP on package labels and not to use more than one product that contains acetaminophen. Instruct patients to seek medical attention immediately upon ingestion of more than 4000 milligrams of acetaminophen per day, even if they feel well.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_68df18d5-b182-443f-b6a0-bc0d8e15c521"></a><a name="section-6.3.2"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>/ <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span></span></p>
<p>There have been post-marketing reports of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> associated with use of acetaminophen. Clinical signs included <span class="product-label-link" type="condition" conceptid="4133326" conceptname="Facial swelling">swelling of face</span>, mouth, and throat, <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. There were infrequent reports of life-threatening <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> requiring emergency medical attention. Instruct patients to discontinue LORTAB 5/500 tablets immediately and seek medical care if they experience these symptoms. Do not prescribe LORTAB 5/500 tablets for patients with acetaminophen <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span>.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_d2e4450b-93fe-4c31-afea-c0a262f2561d"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_d4aad98a-35ea-40cc-94b6-c922ad2a57a1"></a><a name="section-7.1"></a><p></p>
<h2>General</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_de118c3c-62d7-4134-a9ab-999739adee16"></a><a name="section-7.1.1"></a><p></p>
<p class="First">Special Risk Patients</p>
<p>As with any narcotic analgesic agent, LORTAB 5/500 tablets should be used with caution in elderly or debilitated patients, and those with severe impairment of hepatic or renal function, <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>, Addison's disease, <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hypertrophy</span> or <span class="product-label-link" type="condition" conceptid="195590" conceptname="Urethral stricture">urethral stricture</span>. The usual precautions should be observed and the possibility of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> should be kept in mind.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c95779cf-cc03-4c70-8c82-b69c6ac3a2bb"></a><a name="section-7.1.2"></a><p></p>
<p class="First"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span> Reflex</p>
<p>Hydrocodone suppresses the <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> reflex; as with all narcotics, caution should be exercised when LORTAB 5/500 tablets are used postoperatively and in patients with pulmonary disease.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_6be6beec-e029-46fe-89a1-f5ffff4b066a"></a><a name="section-7.2"></a><p></p>
<p class="First"><span class="Bold">Information For Patients/Caregivers </span></p>
<p>Hydrocodone, like all narcotics, may impair mental and/or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery; patients should be cautioned accordingly.</p>
<p>Alcohol and other CNS depressants may produce an additive <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span>, when taken with this combination product, and should be avoided.</p>
<p>Hydrocodone may be habit-forming. Patients should take the drug only for as long as it is prescribed, in the amounts prescribed, and no more frequently than prescribed.</p>
<ul>
<li>Do not take LORTAB 5/500 tablets if you are allergic to any of its ingredients.</li>
<li>If you develop signs of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> such as a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">difficulty breathing</span> stop taking LORTAB 5/500 tablets and contact your healthcare provider immediately.</li>
<li>Do not take more than 4000 milligrams of acetaminophen per day. Call your doctor if you took more than the recommended dose.</li>
</ul>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="i4i_lab_tests_id_d207f3ce-2143-4dab-8371-760f9866fed4"></a><a name="section-7.3"></a><p></p>
<p class="First"><span class="Bold">Laboratory Tests </span></p>
<p>In patients with severe hepatic or <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>, effects of therapy should be monitored with serial liver and/or renal function tests.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_5975581a-25b8-4d58-9c87-9ff4c395acbc"></a><a name="section-7.4"></a><p></p>
<p class="First"><span class="Bold">Drug Interactions </span></p>
<p>Patients receiving other narcotic analgesics, antihistamines, antipsychotics, antianxiety agents, or other CNS depressants (including alcohol) concomitantly with LORTAB 5/500 tablets may exhibit an additive <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span>. When combined therapy is contemplated, the dose of one or both agents should be reduced.</p>
<p>The use of MAO inhibitors or tricyclic antidepressants with hydrocodone preparations may increase the effect of either the antidepressant or hydrocodone.</p>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="i4i_drug_lab_interaction_id_0df3042f-5ca3-4276-83fd-c8a7f4ffe57f"></a><a name="section-7.5"></a><p></p>
<p class="First"><span class="Bold">Drug/Laboratory Test Interactions</span></p>
<p>Acetaminophen may produce false-positive test results for urinary 5-hydroxyindoleacetic acid.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_b55ac456-4098-42a3-8b02-216a3a1e3433"></a><a name="section-7.6"></a><p></p>
<p class="First"><span class="Bold">Carcinogenesis, Mutagenesis, Impairment Of Fertility</span></p>
<p>No adequate studies have been conducted in animals to determine whether hydrocodone or acetaminophen have a potential for carcinogenesis, mutagenesis, or impairment of fertility.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_6ad80800-ffeb-4d39-be04-e6e4aa2e1a1b"></a><a name="section-7.7"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="i4i_teratogenic_id_f55cd2cd-1aa9-41e8-90e5-71c2d0a1a5ab"></a><a name="section-7.7.1"></a><p></p>
<p class="First"> Teratogenic Effects</p>
<p><span class="Italics">Pregnancy Category C</span></p>
<p> There are no adequate and well-controlled studies in pregnant women. LORTAB 5/500 tablets should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="i4i_non_teratogenic_id_f6844d1f-7f24-4791-91b3-88490702df02"></a><a name="section-7.7.2"></a><p></p>
<p class="First">Nonteratogenic Effects</p>
<p>Babies born to mothers who have been taking opioids regularly prior to delivery will be physically dependent. The withdrawal signs include <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span> and excessive <span class="product-label-link" type="condition" conceptid="4136768" conceptname="Crying">crying</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactive</span> reflexes, increased <span class="product-label-link" type="condition" conceptid="4313591" conceptname="Respiratory rate">respiratory rate</span>, increased stools, <span class="product-label-link" type="condition" conceptid="4328356" conceptname="Sneezing">sneezing</span>, <span class="product-label-link" type="condition" conceptid="4089239" conceptname="Yawning">yawning</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>. The intensity of the syndrome does not always correlate with the duration of maternal opioid use or dose. There is no consensus on the best method of managing withdrawal.</p>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="i4i_labour_delivery_id_876d7363-4758-49f5-bc91-393daaa53e9c"></a><a name="section-7.8"></a><p></p>
<p class="First"><span class="Bold">Labor And Delivery </span></p>
<p>As with all narcotics, administration of LORTAB 5/500 tablets to the mother shortly before delivery may result in some degree of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> in the newborn, especially if higher doses are used.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_7e68d8d7-6b5b-4548-a689-3138c9c48eb2"></a><a name="section-7.9"></a><p></p>
<p class="First"><span class="Bold">Nursing Mothers </span></p>
<p>Acetaminophen is excreted in breast milk in small amounts, but the significance of its effects on nursing infants is not known. It is not known whether hydrocodone is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from hydrocodone and acetaminophen, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_fd2517e1-1b28-4e18-bb1e-85b550ad2c1f"></a><a name="section-7.10"></a><p></p>
<p class="First"><span class="Bold">Pediatric Use </span></p>
<p>Safety and effectiveness in the pediatric population have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_625b095c-c184-4c11-a3f2-2734302c5777"></a><a name="section-7.11"></a><p></p>
<p class="First"><span class="Bold">Geriatric Use </span></p>
<p>Clinical studies of LORTAB 5/500 (hydrocodone bitartrate 5 mg and acetaminophen 500 mg) tablets did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>
<p>Hydrocodone and the major metabolites of acetaminophen are known to be substantially excreted by the kidney. Thus the risk of toxic reactions may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> due to the accumulation of the parent compound and/or metabolites in the plasma. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.</p>
<p>Hydrocodone may cause <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> and over-sedation in the elderly; elderly patients generally should be started on low doses of hydrocodone bitartrate and acetaminophen tablets and observed closely.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_58e85ad2-b0ce-4edc-8dbb-464769902422"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">The most frequently reported adverse reactions include: light-headedness, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, sedation, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. These effects seem to be more prominent in ambulatory than in non-ambulatory patients and some of these adverse reactions may be alleviated if the patient lies down.</p>
<p>Other adverse reactions include:</p>
<p><span class="Bold">Central Nervous System</span></p>
<p><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Drowsiness</span>, mental clouding, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, impairment of mental and physical performance, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="4029621" conceptname="Fear">fear</span>, <span class="product-label-link" type="condition" conceptid="4148767" conceptname="Dysphoric mood">dysphoria</span>, psychological <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">mood changes</span>.</p>
<p><span class="Bold">Gastrointestinal System</span></p>
<p>Prolonged administration of LORTAB 5/500 tablets may produce <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>.</p>
<p><span class="Bold">Genitourinary System</span></p>
<p>Ureteral spasm, spasm of vesical sphincters and <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span> have been reported with opiates.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span></span></p>
<p>Hydrocodone bitartrate may produce dose-related <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> by acting directly on the brain stem respiratory centers (<span class="Italics">see </span><span class="Bold"><a href="#i4i_overdosage_id_8e8ea00f-5049-4f0b-ac81-04b2d42f5fba">OVERDOSAGE</a></span>).</p>
<p><span class="Bold">Special Senses</span></p>
<p>Cases of hearing impairment or permanent loss have been reported predominantly in patients with <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">chronic overdose</span>.</p>
<p><span class="Bold">Dermatological</span></p>
<p><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Skin rash</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>.</p>
<p>The following adverse drug events may be borne in mind as potential effects of acetaminophen: <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>.</p>
<p>Potential effects of high dosage are listed in the <span class="Bold"><a href="#i4i_overdosage_id_8e8ea00f-5049-4f0b-ac81-04b2d42f5fba">OVERDOSAGE</a></span> section. </p>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="i4i_abuse_dependence_id_fca7add3-546a-4f72-91e1-17ddc4f99fb9"></a><a name="section-9"></a><p></p>
<h1>DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<div class="Section" data-sectionCode="34085-1">
<a name="i4i_controlled_substance_id_56af4fd0-38c5-4417-b926-4bcdf5e82a83"></a><a name="section-9.1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34086-9">
<a name="i4i_abuse_id_67ea0381-2ce3-410d-b54a-efce6f89efd3"></a><a name="section-9.2"></a><p></p>
<p class="First"><span class="Bold">Misuse, Abuse, And Diversion Of Opioids</span></p>
<p>LORTAB 5/500 tablets contains hydrocodone, an opioid agonist, and is a Schedule III controlled substance. LORTAB 5/500 tablets, and other opioids, used in <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> can be abused and are subject to criminal diversion.</p>
<p>Addiction is a primary, chronic, neurobiologic disease, with genetic, psychosocial, and environmental factors influencing its development and manifestations. It is characterized by behaviors that include one or more of the following: impaired control over drug use, compulsive use, continued use despite harm, and craving. <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">Drug addiction</span> is a treatable disease utilizing a multidisciplinary approach, but relapse is common.</p>
<p>â€œDrug seekingâ€? behavior is very common in addicts and drug abusers. Drug-seeking tactics include emergency calls or visits near the end of office hours, refusal to undergo appropriate examination, testing or referral, repeated â€œlossâ€? of prescriptions, tampering with prescriptions and reluctance to provide prior medical records or contact information for other treating physician(s). â€œDoctor shoppingâ€? to obtain additional prescriptions is common among drug abusers and people suffering from untreated addiction.</p>
<p>Abuse and addiction are separate and distinct from physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> and tolerance. Physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> usually assumes clinically significant dimensions only after several weeks of continued opioid use, although a mild degree of physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> may develop after a few days of opioid therapy. Tolerance, in which increasingly large doses are required in order to produce the same degree of <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span>, is manifested initially by a shortened duration of <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesic effect</span>, and subsequently by decreases in the intensity of <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span>. The rate of development of tolerance varies among patients. Physicians should be aware that abuse of opioids can occur in the absence of true addiction and is characterized by misuse for non-medical purposes, often in combination with other psychoactive substances. LORTAB 5/500 tablets, like other opioids, may be diverted for non-medical use. Record-keeping of prescribing information, including quantity, frequency, and renewal requests is strongly advised.</p>
<p>Proper assessment of the patient, proper prescribing practices, periodic re-evaluation of therapy, and proper dispensing and storage are appropriate measures that help to limit abuse of opioid drugs.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_8e8ea00f-5049-4f0b-ac81-04b2d42f5fba"></a><a name="section-10"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Following an acute overdosage, toxicity may result from hydrocodone or acetaminophen.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_760f604b-2ba1-43ae-99e1-799af52d99bb"></a><a name="section-10.1"></a><p></p>
<h2>Signs And Symptoms</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5a29c3d7-b0c2-439f-9b5c-393153e8f7b4"></a><a name="section-10.1.1"></a><p></p>
<p class="First"> Hydrocodone </p>
<p>Serious <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with hydrocodone is characterized by <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> (a decrease in <span class="product-label-link" type="condition" conceptid="4313591" conceptname="Respiratory rate">respiratory rate</span> and/or tidal volume, Cheyne-Stokes respiration, <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span>) extreme <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> progressing to <span class="product-label-link" type="condition" conceptid="4229897" conceptname="Stupor">stupor</span> or <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, skeletal muscle <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">flaccidity</span>, <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> and <span class="product-label-link" type="condition" conceptid="4308436" conceptname="Cold sweat">clammy</span> skin, and sometimes <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. In severe overdosage, <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>, <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">circulatory collapse</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> may occur.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_cef34f56-0638-42f3-8b18-c3bdc882d442"></a><a name="section-10.1.2"></a><p></p>
<p class="First">Acetaminophen</p>
<p>In acetaminophen overdosage: dose-dependent, potentially fatal <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">hepatic necrosis</span> is the most serious adverse effect. <span class="product-label-link" type="condition" conceptid="444044" conceptname="Acute tubular necrosis">Renal tubular necrosis</span>, <span class="product-label-link" type="condition" conceptid="380688" conceptname="Hypoglycemic coma">hypoglycemic coma</span> and coagulation defects may also occur. Early symptoms following a potentially hepatotoxic <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> may include: <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span> and <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">general malaise</span>. Clinical and laboratory evidence of hepatic toxicity may not be apparent until 48 to 72 hours post-ingestion.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f56f00cf-e0ed-4150-a7b3-4246fbc1074b"></a><a name="section-10.1.3"></a><p></p>
<p class="First"><span class="Bold">Treatment</span></p>
<p>A single or <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">multiple drug overdose</span> with hydrocodone and acetaminophen is a potentially lethal polydrug <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, and consultation with a regional poison control center is recommended. Immediate treatment includes support of cardiorespiratory function and measures to reduce drug absorption. Oxygen, intravenous fluids, vasopressors, and other supportive measures should be employed as indicated. Assisted or controlled ventilation should also be considered.</p>
<p>For hydrocodone <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, primary attention should be given to the reestablishment of adequate respiratory exchange through provision of a patent airway and the institution of assisted or controlled ventilation. The narcotic antagonist naloxone hydrochloride is a specific antidote against <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> which may result from overdosage or unusual sensitivity to narcotics, including hydrocodone. Since the duration of action of hydrocodone may exceed that of the antagonist, the patient should be kept under continued surveillance, and repeated doses of the antagonist should be administered as needed to maintain adequate respiration. A narcotic antagonist should not be administered in the absence of clinically significant respiratory or cardiovascular <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>.</p>
<p>Gastric decontamination with activated charcoal should be administered just prior to N-acetylcysteine (NAC) to decrease systemic absorption if acetaminophen ingestion is known or suspected to have occurred within a few hours of presentation. Serum acetaminophen levels should be obtained immediately if the patient presents 4 hours or more after ingestion to assess potential risk of hepatotoxicity; acetaminophen levels drawn less than 4 hours post-ingestion may be misleading. To obtain the best possible outcome, NAC should be administered as soon as possible where impending or evolving <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> is suspected. Intravenous NAC may be administered when circumstances preclude oral administration.</p>
<p>Vigorous supportive therapy is required in severe <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span>. Procedures to limit the continuing absorption of the drug must be readily performed since the hepatic injury is dose dependent and occurs early in the course of <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span>. </p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_b19ba905-5ae4-4f5f-8246-7fa7cb9bd65c"></a><a name="section-11"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Dosage should be adjusted according to severity of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and response of the patient. However, it should be kept in mind that tolerance to hydrocodone can develop with continued use and that the incidence of untoward effects is dose related.</p>
<p>The usual adult dosage is one or two tablets every four to six hours as needed for <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. The total daily dosage should not exceed 8 tablets.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_68f2a4ea-1fc3-4a78-855e-91a8b80ae350"></a><a name="section-12"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">LORTAB<span class="Sup">Â®</span> 5/500 tablets (hydrocodone bitartrate and acetaminophen tablets, USP, 5 mg/500 mg) contain hydrocodone bitartrate 5 mg and acetaminophen 500 mg. They are supplied as white with blue specks, capsule-shaped, bisected tablets, debossed "ucb" on one side and "902" on the other side, in containers of 100 tablets NDC 50474-902-01 and 500 tablets NDC 50474-902-50.</p>
<div class="Section" data-sectionCode="44425-7">
<a name="i4i_storage_id_a0191862-e4c7-42fb-a536-398d496bb0d1"></a><a name="section-12.1"></a><p></p>
<p class="First"><span class="Bold">Storage</span></p>
<p>Store at 20 to 25Â°C (68 to 77Â°F). [see USP Controlled Room Temperature]</p>
<p> Dispense in a tight, light-resistant container (as defined in the USP) with a child-resistant closure.</p>
<p><span class="Bold">For Medical Information</span></p>
<p>Contact: Medical Affairs Department<br>Phone: (866) 822-0068<br>Fax: (770) 970-8859</p>
<p>A Schedule CIII controlled drug substance.</p>
<p><span class="Bold">UCB Pharma, Inc.</span></p>
<p>Smyrna, GA 30080</p>
<p>Manufactured by</p>
<p><span class="Bold">Mallinckrodt Inc.</span></p>
<p>Hobart, NY 13788</p>
<p>Rev. 5E 05/2011</p>
<p>CIA70083C</p>
<p>L2LL03</p>
<p><span class="Bold">Repackaged by RxPak</span></p>
<p><span class="Bold">Division of McKesson Corp.</span></p>
<p><span class="Bold">Memphis, TN 38141</span></p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_5a6f928d-a196-4f5b-b7dc-f05c05e01290"></a><a name="section-13"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<p class="First"><img alt="Lortab 5mg-500mg Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6e48680d-b4ea-4eca-86ab-d9eb3434855b&amp;name=6e48680d-b4ea-4eca-86ab-d9eb3434855b-03.jpg"></p>
<p>    Â <span class="Bold">100 TABLETS</span></p>
<p><span class="Bold">LORTAB<span class="Sup">Â®</span> 5/500</span></p>
<p>HYDROCODONE BITARTRATE <br>AND ACETAMINOPHEN <br>TABLETS, USP <br>5 mg/500 mg</p>
<p>Each scored, white with blue specks tablet <br>contains:</p>
<a name="id_cccd9e01-e595-408d-a3c6-4068e6191222"></a><table>
<col align="left" width="50%">
<col align="right" width="50%">
<tbody class="Headless">
<tr class="First Toprule">
<td align="left" valign="top">Hydrocodone Bitartrate</td>
<td align="left" valign="top">5 mg</td>
</tr>
<tr class="Botrule Last">
<td align="left" valign="top">Acetaminophen</td>
<td align="left" valign="top">500 mg</td>
</tr>
</tbody>
</table>
<p><span class="Bold">Rx only</span></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>LORTABÂ 		
					</strong><br><span class="contentTableReg">hydrocodone bitartrate and acetaminophen tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:65084-287(NDC:50474-902)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CIIIÂ Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>hydrocodone bitartrate</strong> (hydrocodone) </td>
<td class="formItem">hydrocodone bitartrate</td>
<td class="formItem">5Â mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>acetaminophen</strong> (acetaminophen) </td>
<td class="formItem">acetaminophen</td>
<td class="formItem">500Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>starch, corn</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C Blue No. 1</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>aluminum oxide</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>gelatin</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>cellulose, microcrystalline</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONES</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (blue specks) </td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (capsule-shaped) </td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">ucb;902</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:65084-287-10</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA087722</td>
<td class="formItem">02/28/2002</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Rx Pak Division of McKesson Corporation
							(025183281)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Rx Pak Division of McKesson Corporation</td>
<td class="formItem"></td>
<td class="formItem">025183281</td>
<td class="formItem">REPACK(65084-287)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 8/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>6e48680d-b4ea-4eca-86ab-d9eb3434855b</div>
<div>Set id: 6e48680d-b4ea-4eca-86ab-d9eb3434855b</div>
<div>Version: 1</div>
<div>Effective Time: 20130812</div>
</div>
</div>Â <div class="DistributorName">Rx Pak Division of McKesson Corporation</div></p>
</body></html>
